Comparing the current results to its competitors, Quanterix reported Revenue increase in the 2 quarter 2026 by 35.42 % year on year. The sales growth was above Quanterix's competitors' average revenue growth of 8.95 %, achieved in the same quarter.
Quanterix Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 7.71 %
Quanterix's Comment on Competition and Industry Peers
The company operates in a competitive market alongside both established and development-stage life science firms that design, manufacture, and market instruments for proteomics discovery and clinical research applications. Competitors include Bio-Techne, MesoScale Discovery, SEER, Bio-Rad Laboratories, Alamar, Spear Bio, Roche, Fujirebio, Danaher, and C2N Diagnostics. These companies offer products for protein measurement in biofluids, spatial biology, diagnostics, and non-invasive early disease detection. The life science instrumentation and laboratory services industries are highly competitive and are expected to become more so with ongoing research and development.
Strong sales growth of 35.42 % in Overall company contributed to Quanterix Corporation increase in total revenue by 35.42 % Quanterix Corporation improved its market share in this segment, to approximately 0.19 %.
March 18, 2025
Quanterix Corporation Reports Strong Financial Growth Amid Industry Challenges: A Q4 2024 Analysis In a notable demonstration of resilience and strategic execution, Quanterix Corporation (NASDAQ: QTRX), a leader in ultra-sensitive biomarker detection, announced its financial results for the fourth quarter of 2024, spotlighting an 11% revenue growth. This achievement marks the company s seventh consecutive quarter of double-digit growth, a remarkable feat in the context of a capital-constrained environment that has challenged many players in the biotechnology sector.Masoud Toloue, the Chief Executive Officer of Quanterix, expressed pride in the company’s performance, stating, Our ability to grow in a diffic...
November 25, 2024
Quanterix Faces Nasdaq Compliance Challenge Amidst Market Struggles In a rather somber turn of events for Quanterix Corporation, the biotechnology firm based in Billerica, Massachusetts, has been formally notified by The Nasdaq Stock Market LLC of its non-compliance with listing regulations. As of November 21, 2024, Quanterix received a Notice indicating that the company failed to file its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024. This missed deadline places the company in violation of Nasdaq Listing Rule 5250(c)(1), which mandates all listed entities to submit periodic financial reports in a timely manner.The notice comes at a precarious time for Quanterix, as its shares have ...
October 1, 2024
Quanterix Commercializes p-Tau 217 Test Kit Amid Competitive Market Landscape Quanterix Corporation (NASDAQ: QTRX), a leader in ultrasensitive biomarker detection technology, has made significant strides in advancing diagnostic testing for Alzheimer’s Disease (AD). The company announced the commercial release of its Simoa p-Tau 217 Planar Kit, marking an important step forward in the realm of AD test development. This kit employs proprietary p-Tau 217 antibody technology, licensed from Eli Lilly and Company, utilized through Quanterix’s SP-X platform. The release aims to enhance scientific discovery and provide more precise diagnostic options for one of the most challenging neurodegenerative diseases.The...
September 30, 2024
In a significant stride for Alzheimer’s disease (AD) diagnostics, Quanterix Corporation (NASDAQ: QTRX) announced the commercial launch of its Simoa p-Tau 217 Planar Kit. This cutting-edge test kit, benefiting from the company’s pioneering ultrasensitive biomarker detection technology and a breakthrough antibody licensed from Eli Lilly and Company, aims to enhance the accuracy and efficiency of Alzheimer’s testing a critical need as the global population ages and AD incidence rises.Alzheimer s disease has long posed diagnostic challenges, with existing methods often falling short in sensitivity and specificity. The introduction of the p-Tau 217 test kit represents a watershed moment in the field, harn...
February 26, 2024
Quanterix Corporation, a prominent provider of ultra-sensitive research products and high-definition diagnostics, has recently announced its first collaborations with five major health networks. The aim of these collaborations is to enhance the diagnosis and clinical management of individuals suffering from Alzheimer s disease (AD). By expanding clinical access to its leading blood biomarker assays, Quanterix strives to facilitate the improvement and simplification of AD diagnosis worldwide. The partnerships established by Quanterix reflect the company s dedication to building a robust global infrastructure for AD testing. Through these collaborations, Quanterix aims to leverage the expertise and resources o...
Agilent Technologies Inc. operates a business model centered on delivering innovative measurement solutions across industries like life sciences, diagnostics, and chemical analysis. Their revenue primarily comes from sales of instruments, software, and consumables, supplemented by support services. The company emphasizes strong partnerships and collaborations to enhance their market presence and influence.
Rapid Micro Biosystems Inc has a business model centered around providing automated microbial detection and enumeration solutions for pharmaceutical companies, ensuring streamlined and efficient quality control processes. Their innovative technology enables rapid detection of microbial contamination in products, reducing the need for manual intervention and accelerating time-to-results for manufacturers.
Sources:
Quanterix Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Quanterix Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
